Biotech Values

[poorgradstudent]

Not sure what you mean here as producing immune response is exactly what IO is....is it not?

Trillium's drug is a fusion between an antibody's constant region and SIRPa. The fusion point is not a native sequence, and therefore can be recognized by the host's immune response (see DNDN). If this happens, the drug that gets infused could be cleared out by the patient just as quickly, thereby negating the therapy.

These sequences can be modeled and "de-immunized" but i'm not aware of any data to suggest that this has been explicitly done.